Biosimilars and biologics :: implementation and monitoring in a healthcare setting /
Get Up to Speed on the Fastest Growing Pharmaceutical Innovation With the Only Guide Written for Pharmacists Among the most anticipated and discussed segments of the pharmaceutical market, biosimilars, are finally beginning to exert a greater impact on practice. To meet the growing need for informat...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Bethesda, MD :
American Society of Health-System Pharmacists, Inc.,
[2018]
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | Get Up to Speed on the Fastest Growing Pharmaceutical Innovation With the Only Guide Written for Pharmacists Among the most anticipated and discussed segments of the pharmaceutical market, biosimilars, are finally beginning to exert a greater impact on practice. To meet the growing need for information, ASHP has published Biosimilars and Biologics. This authoritative, evidence-based resource provides an in-depth perspective on all areas related to these innovative drugs, including: · Legislative/regulatory issues, including the biosimilars act and anticipated FDA guidelines · |
| Beschreibung: | 1 online resource |
| Bibliographie: | Includes bibliographical references and index. |
| ISBN: | 9781585285815 1585285811 |
Internformat
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-on1039079127 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 180607s2018 mdu ob 001 0 eng d | ||
| 040 | |a N$T |b eng |e rda |e pn |c N$T |d OCLCO |d YDX |d EBLCP |d MERUC |d N$T |d UAB |d OCLCF |d OCLCQ |d DKU |d OCLCO |d OCLCA |d OCLCQ |d K6U |d OCLCA |d OCLCQ |d OCLCO |d LUU |d OCLCQ |d OCLCO |d OCLCL |d SXB | ||
| 020 | |a 9781585285815 |q (electronic bk.) | ||
| 020 | |a 1585285811 |q (electronic bk.) | ||
| 020 | |z 9781585285808 | ||
| 020 | |z 1585285803 | ||
| 035 | |a (OCoLC)1039079127 | ||
| 050 | 4 | |a RS380 | |
| 060 | 1 | 0 | |a QV 241 |
| 072 | 7 | |a MED |x 071000 |2 bisacsh | |
| 082 | 7 | |a 615.1/9 |2 23 | |
| 049 | |a MAIN | ||
| 100 | 1 | |a Lucio, Steven, |e author. |0 http://id.loc.gov/authorities/names/n2017190033 | |
| 245 | 1 | 0 | |a Biosimilars and biologics : |b implementation and monitoring in a healthcare setting / |c Steven Lucio. |
| 264 | 1 | |a Bethesda, MD : |b American Society of Health-System Pharmacists, Inc., |c [2018] | |
| 264 | 4 | |c ©2018 | |
| 300 | |a 1 online resource | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |a A new type of blockbuster : the growth of biologics -- Déjá vu or something new? : comparing the generics and biosimilars experiences -- Bugs and drugs, and yeast and mice, and Chinese hamsters -- The $250 billion pyramid : analytics in biosimilarity determination -- The global biosimilars experience -- The American biosimilar experience : red, white, and possibly interchangeable -- Biosimilar clinical trial requirements -- Immunogenicity and pharmacovigilance in the biosimilar era -- The patent dance and the exclusivity shuffle -- Defining biosimilar value and other impossible tasks -- Biosimilar formulary management strategies. | |
| 588 | 0 | |a Online resource; title from PDF title page (EBSCO, viewed August 8, 2018). | |
| 520 | |a Get Up to Speed on the Fastest Growing Pharmaceutical Innovation With the Only Guide Written for Pharmacists Among the most anticipated and discussed segments of the pharmaceutical market, biosimilars, are finally beginning to exert a greater impact on practice. To meet the growing need for information, ASHP has published Biosimilars and Biologics. This authoritative, evidence-based resource provides an in-depth perspective on all areas related to these innovative drugs, including: · Legislative/regulatory issues, including the biosimilars act and anticipated FDA guidelines · | ||
| 650 | 0 | |a Pharmaceutical biotechnology. |0 http://id.loc.gov/authorities/subjects/sh90004049 | |
| 650 | 0 | |a Pharmaceutical biotechnology industry. |0 http://id.loc.gov/authorities/subjects/sh00005579 | |
| 650 | 0 | |a Drugs |x Generic substitution. |0 http://id.loc.gov/authorities/subjects/sh85039731 | |
| 650 | 0 | |a Pharmaceutical policy. |0 http://id.loc.gov/authorities/subjects/sh85100588 | |
| 650 | 0 | |a Biological products. |0 http://id.loc.gov/authorities/subjects/sh85014183 | |
| 650 | 2 | |a Biosimilar Pharmaceuticals | |
| 650 | 2 | |a Drug Compounding | |
| 650 | 2 | |a Drug Monitoring | |
| 650 | 2 | |a Biological Factors |0 https://id.nlm.nih.gov/mesh/D001685 | |
| 650 | 6 | |a Biotechnologie pharmaceutique. | |
| 650 | 6 | |a Biotechnologie pharmaceutique |x Industrie. | |
| 650 | 6 | |a Médicaments |x Dénomination commune. | |
| 650 | 6 | |a Médicaments |x Politique gouvernementale. | |
| 650 | 6 | |a Produits biologiques. | |
| 650 | 6 | |a Médicaments biosimilaires. | |
| 650 | 6 | |a Pharmacovigilance. | |
| 650 | 7 | |a MEDICAL |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a Biological products |2 fast | |
| 650 | 7 | |a Drugs |x Generic substitution |2 fast | |
| 650 | 7 | |a Pharmaceutical biotechnology |2 fast | |
| 650 | 7 | |a Pharmaceutical biotechnology industry |2 fast | |
| 650 | 7 | |a Pharmaceutical policy |2 fast | |
| 655 | 4 | |a Electronic book. | |
| 758 | |i has work: |a Biosimilars and biologics (Text) |1 https://id.oclc.org/worldcat/entity/E39PCFxRGbRRYQwHhdGftDmkMq |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1825168 |3 Volltext |
| 938 | |a EBL - Ebook Library |b EBLB |n EBL5412768 | ||
| 938 | |a EBSCOhost |b EBSC |n 1825168 | ||
| 938 | |a YBP Library Services |b YANK |n 15498940 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-on1039079127 |
|---|---|
| _version_ | 1816882461553983488 |
| adam_text | |
| any_adam_object | |
| author | Lucio, Steven |
| author_GND | http://id.loc.gov/authorities/names/n2017190033 |
| author_facet | Lucio, Steven |
| author_role | aut |
| author_sort | Lucio, Steven |
| author_variant | s l sl |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RS380 |
| callnumber-raw | RS380 |
| callnumber-search | RS380 |
| callnumber-sort | RS 3380 |
| callnumber-subject | RS - Pharmacy |
| collection | ZDB-4-EBA |
| contents | A new type of blockbuster : the growth of biologics -- Déjá vu or something new? : comparing the generics and biosimilars experiences -- Bugs and drugs, and yeast and mice, and Chinese hamsters -- The $250 billion pyramid : analytics in biosimilarity determination -- The global biosimilars experience -- The American biosimilar experience : red, white, and possibly interchangeable -- Biosimilar clinical trial requirements -- Immunogenicity and pharmacovigilance in the biosimilar era -- The patent dance and the exclusivity shuffle -- Defining biosimilar value and other impossible tasks -- Biosimilar formulary management strategies. |
| ctrlnum | (OCoLC)1039079127 |
| dewey-full | 615.1/9 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.1/9 |
| dewey-search | 615.1/9 |
| dewey-sort | 3615.1 19 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04353cam a2200721 i 4500</leader><controlfield tag="001">ZDB-4-EBA-on1039079127</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr cnu---unuuu</controlfield><controlfield tag="008">180607s2018 mdu ob 001 0 eng d</controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">N$T</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="e">pn</subfield><subfield code="c">N$T</subfield><subfield code="d">OCLCO</subfield><subfield code="d">YDX</subfield><subfield code="d">EBLCP</subfield><subfield code="d">MERUC</subfield><subfield code="d">N$T</subfield><subfield code="d">UAB</subfield><subfield code="d">OCLCF</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">DKU</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCA</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">K6U</subfield><subfield code="d">OCLCA</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">LUU</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCL</subfield><subfield code="d">SXB</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781585285815</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1585285811</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9781585285808</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">1585285803</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1039079127</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RS380</subfield></datafield><datafield tag="060" ind1="1" ind2="0"><subfield code="a">QV 241</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">071000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">615.1/9</subfield><subfield code="2">23</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Lucio, Steven,</subfield><subfield code="e">author.</subfield><subfield code="0">http://id.loc.gov/authorities/names/n2017190033</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Biosimilars and biologics :</subfield><subfield code="b">implementation and monitoring in a healthcare setting /</subfield><subfield code="c">Steven Lucio.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Bethesda, MD :</subfield><subfield code="b">American Society of Health-System Pharmacists, Inc.,</subfield><subfield code="c">[2018]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">©2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">A new type of blockbuster : the growth of biologics -- Déjá vu or something new? : comparing the generics and biosimilars experiences -- Bugs and drugs, and yeast and mice, and Chinese hamsters -- The $250 billion pyramid : analytics in biosimilarity determination -- The global biosimilars experience -- The American biosimilar experience : red, white, and possibly interchangeable -- Biosimilar clinical trial requirements -- Immunogenicity and pharmacovigilance in the biosimilar era -- The patent dance and the exclusivity shuffle -- Defining biosimilar value and other impossible tasks -- Biosimilar formulary management strategies.</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Online resource; title from PDF title page (EBSCO, viewed August 8, 2018).</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Get Up to Speed on the Fastest Growing Pharmaceutical Innovation With the Only Guide Written for Pharmacists Among the most anticipated and discussed segments of the pharmaceutical market, biosimilars, are finally beginning to exert a greater impact on practice. To meet the growing need for information, ASHP has published Biosimilars and Biologics. This authoritative, evidence-based resource provides an in-depth perspective on all areas related to these innovative drugs, including: · Legislative/regulatory issues, including the biosimilars act and anticipated FDA guidelines ·</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Pharmaceutical biotechnology.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh90004049</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Pharmaceutical biotechnology industry.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh00005579</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Drugs</subfield><subfield code="x">Generic substitution.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85039731</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Pharmaceutical policy.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85100588</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Biological products.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85014183</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Biosimilar Pharmaceuticals</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Drug Compounding</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Drug Monitoring</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Biological Factors</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D001685</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Biotechnologie pharmaceutique.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Biotechnologie pharmaceutique</subfield><subfield code="x">Industrie.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Médicaments</subfield><subfield code="x">Dénomination commune.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Médicaments</subfield><subfield code="x">Politique gouvernementale.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Produits biologiques.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Médicaments biosimilaires.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Pharmacovigilance.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Pharmacology.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Biological products</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drugs</subfield><subfield code="x">Generic substitution</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical biotechnology</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical biotechnology industry</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical policy</subfield><subfield code="2">fast</subfield></datafield><datafield tag="655" ind1=" " ind2="4"><subfield code="a">Electronic book.</subfield></datafield><datafield tag="758" ind1=" " ind2=" "><subfield code="i">has work:</subfield><subfield code="a">Biosimilars and biologics (Text)</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PCFxRGbRRYQwHhdGftDmkMq</subfield><subfield code="4">https://id.oclc.org/worldcat/ontology/hasWork</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1825168</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBL - Ebook Library</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL5412768</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">1825168</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">15498940</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| genre | Electronic book. |
| genre_facet | Electronic book. |
| id | ZDB-4-EBA-on1039079127 |
| illustrated | Not Illustrated |
| indexdate | 2024-11-27T13:28:59Z |
| institution | BVB |
| isbn | 9781585285815 1585285811 |
| language | English |
| oclc_num | 1039079127 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource |
| psigel | ZDB-4-EBA |
| publishDate | 2018 |
| publishDateSearch | 2018 |
| publishDateSort | 2018 |
| publisher | American Society of Health-System Pharmacists, Inc., |
| record_format | marc |
| spelling | Lucio, Steven, author. http://id.loc.gov/authorities/names/n2017190033 Biosimilars and biologics : implementation and monitoring in a healthcare setting / Steven Lucio. Bethesda, MD : American Society of Health-System Pharmacists, Inc., [2018] ©2018 1 online resource text txt rdacontent computer c rdamedia online resource cr rdacarrier Includes bibliographical references and index. A new type of blockbuster : the growth of biologics -- Déjá vu or something new? : comparing the generics and biosimilars experiences -- Bugs and drugs, and yeast and mice, and Chinese hamsters -- The $250 billion pyramid : analytics in biosimilarity determination -- The global biosimilars experience -- The American biosimilar experience : red, white, and possibly interchangeable -- Biosimilar clinical trial requirements -- Immunogenicity and pharmacovigilance in the biosimilar era -- The patent dance and the exclusivity shuffle -- Defining biosimilar value and other impossible tasks -- Biosimilar formulary management strategies. Online resource; title from PDF title page (EBSCO, viewed August 8, 2018). Get Up to Speed on the Fastest Growing Pharmaceutical Innovation With the Only Guide Written for Pharmacists Among the most anticipated and discussed segments of the pharmaceutical market, biosimilars, are finally beginning to exert a greater impact on practice. To meet the growing need for information, ASHP has published Biosimilars and Biologics. This authoritative, evidence-based resource provides an in-depth perspective on all areas related to these innovative drugs, including: · Legislative/regulatory issues, including the biosimilars act and anticipated FDA guidelines · Pharmaceutical biotechnology. http://id.loc.gov/authorities/subjects/sh90004049 Pharmaceutical biotechnology industry. http://id.loc.gov/authorities/subjects/sh00005579 Drugs Generic substitution. http://id.loc.gov/authorities/subjects/sh85039731 Pharmaceutical policy. http://id.loc.gov/authorities/subjects/sh85100588 Biological products. http://id.loc.gov/authorities/subjects/sh85014183 Biosimilar Pharmaceuticals Drug Compounding Drug Monitoring Biological Factors https://id.nlm.nih.gov/mesh/D001685 Biotechnologie pharmaceutique. Biotechnologie pharmaceutique Industrie. Médicaments Dénomination commune. Médicaments Politique gouvernementale. Produits biologiques. Médicaments biosimilaires. Pharmacovigilance. MEDICAL Pharmacology. bisacsh Biological products fast Drugs Generic substitution fast Pharmaceutical biotechnology fast Pharmaceutical biotechnology industry fast Pharmaceutical policy fast Electronic book. has work: Biosimilars and biologics (Text) https://id.oclc.org/worldcat/entity/E39PCFxRGbRRYQwHhdGftDmkMq https://id.oclc.org/worldcat/ontology/hasWork FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1825168 Volltext |
| spellingShingle | Lucio, Steven Biosimilars and biologics : implementation and monitoring in a healthcare setting / A new type of blockbuster : the growth of biologics -- Déjá vu or something new? : comparing the generics and biosimilars experiences -- Bugs and drugs, and yeast and mice, and Chinese hamsters -- The $250 billion pyramid : analytics in biosimilarity determination -- The global biosimilars experience -- The American biosimilar experience : red, white, and possibly interchangeable -- Biosimilar clinical trial requirements -- Immunogenicity and pharmacovigilance in the biosimilar era -- The patent dance and the exclusivity shuffle -- Defining biosimilar value and other impossible tasks -- Biosimilar formulary management strategies. Pharmaceutical biotechnology. http://id.loc.gov/authorities/subjects/sh90004049 Pharmaceutical biotechnology industry. http://id.loc.gov/authorities/subjects/sh00005579 Drugs Generic substitution. http://id.loc.gov/authorities/subjects/sh85039731 Pharmaceutical policy. http://id.loc.gov/authorities/subjects/sh85100588 Biological products. http://id.loc.gov/authorities/subjects/sh85014183 Biosimilar Pharmaceuticals Drug Compounding Drug Monitoring Biological Factors https://id.nlm.nih.gov/mesh/D001685 Biotechnologie pharmaceutique. Biotechnologie pharmaceutique Industrie. Médicaments Dénomination commune. Médicaments Politique gouvernementale. Produits biologiques. Médicaments biosimilaires. Pharmacovigilance. MEDICAL Pharmacology. bisacsh Biological products fast Drugs Generic substitution fast Pharmaceutical biotechnology fast Pharmaceutical biotechnology industry fast Pharmaceutical policy fast |
| subject_GND | http://id.loc.gov/authorities/subjects/sh90004049 http://id.loc.gov/authorities/subjects/sh00005579 http://id.loc.gov/authorities/subjects/sh85039731 http://id.loc.gov/authorities/subjects/sh85100588 http://id.loc.gov/authorities/subjects/sh85014183 https://id.nlm.nih.gov/mesh/D001685 |
| title | Biosimilars and biologics : implementation and monitoring in a healthcare setting / |
| title_auth | Biosimilars and biologics : implementation and monitoring in a healthcare setting / |
| title_exact_search | Biosimilars and biologics : implementation and monitoring in a healthcare setting / |
| title_full | Biosimilars and biologics : implementation and monitoring in a healthcare setting / Steven Lucio. |
| title_fullStr | Biosimilars and biologics : implementation and monitoring in a healthcare setting / Steven Lucio. |
| title_full_unstemmed | Biosimilars and biologics : implementation and monitoring in a healthcare setting / Steven Lucio. |
| title_short | Biosimilars and biologics : |
| title_sort | biosimilars and biologics implementation and monitoring in a healthcare setting |
| title_sub | implementation and monitoring in a healthcare setting / |
| topic | Pharmaceutical biotechnology. http://id.loc.gov/authorities/subjects/sh90004049 Pharmaceutical biotechnology industry. http://id.loc.gov/authorities/subjects/sh00005579 Drugs Generic substitution. http://id.loc.gov/authorities/subjects/sh85039731 Pharmaceutical policy. http://id.loc.gov/authorities/subjects/sh85100588 Biological products. http://id.loc.gov/authorities/subjects/sh85014183 Biosimilar Pharmaceuticals Drug Compounding Drug Monitoring Biological Factors https://id.nlm.nih.gov/mesh/D001685 Biotechnologie pharmaceutique. Biotechnologie pharmaceutique Industrie. Médicaments Dénomination commune. Médicaments Politique gouvernementale. Produits biologiques. Médicaments biosimilaires. Pharmacovigilance. MEDICAL Pharmacology. bisacsh Biological products fast Drugs Generic substitution fast Pharmaceutical biotechnology fast Pharmaceutical biotechnology industry fast Pharmaceutical policy fast |
| topic_facet | Pharmaceutical biotechnology. Pharmaceutical biotechnology industry. Drugs Generic substitution. Pharmaceutical policy. Biological products. Biosimilar Pharmaceuticals Drug Compounding Drug Monitoring Biological Factors Biotechnologie pharmaceutique. Biotechnologie pharmaceutique Industrie. Médicaments Dénomination commune. Médicaments Politique gouvernementale. Produits biologiques. Médicaments biosimilaires. Pharmacovigilance. MEDICAL Pharmacology. Biological products Drugs Generic substitution Pharmaceutical biotechnology Pharmaceutical biotechnology industry Pharmaceutical policy Electronic book. |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1825168 |
| work_keys_str_mv | AT luciosteven biosimilarsandbiologicsimplementationandmonitoringinahealthcaresetting |